出院COVID-19患者SARS-CoV-2病毒RNA再阳性的差异

IF 1.9 4区 医学 Q4 IMMUNOLOGY
Jiliang Xia, Ying Zeng, Zhenghong Tan, Ting Chen, Weilan Hu, Shulei Shuai, Deliang Cao, Xi Zeng
{"title":"出院COVID-19患者SARS-CoV-2病毒RNA再阳性的差异","authors":"Jiliang Xia,&nbsp;Ying Zeng,&nbsp;Zhenghong Tan,&nbsp;Ting Chen,&nbsp;Weilan Hu,&nbsp;Shulei Shuai,&nbsp;Deliang Cao,&nbsp;Xi Zeng","doi":"10.24875/AIDSRev.21000023","DOIUrl":null,"url":null,"abstract":"<p><p>The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly infectious RNA coronavirus responsible for the pandemic of the coronavirus disease 2019 (COVID-19). Recent advances in virology, epidemiology, diagnosis, and clinical management of COVID-19 have contributed to the control and prevention of this disease, but re-positivity of SARS-CoV-2 in recovered COVID-19 patients has brought a new challenge for this worldwide anti-viral battle. Reverse transcription polymerase chain reaction (RT-PCR) tests of the SARS-CoV-2 pathogen is widely used in clinical diagnosis, but a positive RT-PCR result may be multifactorial, including false positive, SARS-CoV-2 RNA fragment shedding, reinfection of SARS-CoV-2, or re-activation of COVID-19. Re-infection of SARS-CoV-2 or re-activation of COVID-19 is an indicator of live viral carriers and isolation/treatment is needed, but SARS-CoV-2 RNA fragment shedding is not. SARS-CoV-2 RNA is recently reported to integrate into the host genome, but the far-reaching outcome is currently unclear. Therefore, it is critical for appropriate manipulation and prevention of COVID-19 to distinguish these causal factors of SARS-CoV-2 re-positivity. In this review article, we updated the current knowledge of SARS-CoV-2 re-positivity in discharged COVID-19 patients with a focus on re-infection and re-activation. We proposed a hypothetical flowchart for handling of the SARS-CoV-2 re-positive cases.</p>","PeriodicalId":7685,"journal":{"name":"AIDS reviews","volume":"23 3","pages":"153-163"},"PeriodicalIF":1.9000,"publicationDate":"2021-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Differentials of SARS-CoV-2 Viral RNA Re-positivity in Discharged COVID-19 Patients.\",\"authors\":\"Jiliang Xia,&nbsp;Ying Zeng,&nbsp;Zhenghong Tan,&nbsp;Ting Chen,&nbsp;Weilan Hu,&nbsp;Shulei Shuai,&nbsp;Deliang Cao,&nbsp;Xi Zeng\",\"doi\":\"10.24875/AIDSRev.21000023\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly infectious RNA coronavirus responsible for the pandemic of the coronavirus disease 2019 (COVID-19). Recent advances in virology, epidemiology, diagnosis, and clinical management of COVID-19 have contributed to the control and prevention of this disease, but re-positivity of SARS-CoV-2 in recovered COVID-19 patients has brought a new challenge for this worldwide anti-viral battle. Reverse transcription polymerase chain reaction (RT-PCR) tests of the SARS-CoV-2 pathogen is widely used in clinical diagnosis, but a positive RT-PCR result may be multifactorial, including false positive, SARS-CoV-2 RNA fragment shedding, reinfection of SARS-CoV-2, or re-activation of COVID-19. Re-infection of SARS-CoV-2 or re-activation of COVID-19 is an indicator of live viral carriers and isolation/treatment is needed, but SARS-CoV-2 RNA fragment shedding is not. SARS-CoV-2 RNA is recently reported to integrate into the host genome, but the far-reaching outcome is currently unclear. Therefore, it is critical for appropriate manipulation and prevention of COVID-19 to distinguish these causal factors of SARS-CoV-2 re-positivity. In this review article, we updated the current knowledge of SARS-CoV-2 re-positivity in discharged COVID-19 patients with a focus on re-infection and re-activation. We proposed a hypothetical flowchart for handling of the SARS-CoV-2 re-positive cases.</p>\",\"PeriodicalId\":7685,\"journal\":{\"name\":\"AIDS reviews\",\"volume\":\"23 3\",\"pages\":\"153-163\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2021-06-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"AIDS reviews\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.24875/AIDSRev.21000023\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"AIDS reviews","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.24875/AIDSRev.21000023","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 1

摘要

新型严重急性呼吸综合征冠状病毒2 (SARS-CoV-2)是一种高传染性RNA冠状病毒,是2019年冠状病毒病(COVID-19)大流行的罪魁祸首。近年来,新冠肺炎病毒学、流行病学、诊断和临床管理等方面的新进展为新冠肺炎的控制和预防做出了贡献,但新冠肺炎康复患者中SARS-CoV-2的再阳性给全球范围内的抗病毒斗争带来了新的挑战。SARS-CoV-2病原体逆转录聚合酶链反应(RT-PCR)检测广泛用于临床诊断,但RT-PCR阳性结果可能是多因素的,包括假阳性、SARS-CoV-2 RNA片段脱落、SARS-CoV-2再感染或COVID-19再激活。再次感染SARS-CoV-2或重新激活COVID-19是活病毒携带者的指标,需要进行分离/治疗,但不需要脱落SARS-CoV-2 RNA片段。最近有报道称SARS-CoV-2 RNA整合到宿主基因组中,但目前尚不清楚其影响深远的结果。因此,区分这些导致SARS-CoV-2再阳性的因素,对合理操纵和预防COVID-19至关重要。在这篇综述文章中,我们更新了目前关于出院COVID-19患者SARS-CoV-2再阳性的知识,重点是再感染和再激活。我们提出了一个假设的SARS-CoV-2再阳性病例处理流程图。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Differentials of SARS-CoV-2 Viral RNA Re-positivity in Discharged COVID-19 Patients.

The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly infectious RNA coronavirus responsible for the pandemic of the coronavirus disease 2019 (COVID-19). Recent advances in virology, epidemiology, diagnosis, and clinical management of COVID-19 have contributed to the control and prevention of this disease, but re-positivity of SARS-CoV-2 in recovered COVID-19 patients has brought a new challenge for this worldwide anti-viral battle. Reverse transcription polymerase chain reaction (RT-PCR) tests of the SARS-CoV-2 pathogen is widely used in clinical diagnosis, but a positive RT-PCR result may be multifactorial, including false positive, SARS-CoV-2 RNA fragment shedding, reinfection of SARS-CoV-2, or re-activation of COVID-19. Re-infection of SARS-CoV-2 or re-activation of COVID-19 is an indicator of live viral carriers and isolation/treatment is needed, but SARS-CoV-2 RNA fragment shedding is not. SARS-CoV-2 RNA is recently reported to integrate into the host genome, but the far-reaching outcome is currently unclear. Therefore, it is critical for appropriate manipulation and prevention of COVID-19 to distinguish these causal factors of SARS-CoV-2 re-positivity. In this review article, we updated the current knowledge of SARS-CoV-2 re-positivity in discharged COVID-19 patients with a focus on re-infection and re-activation. We proposed a hypothetical flowchart for handling of the SARS-CoV-2 re-positive cases.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
AIDS reviews
AIDS reviews 医学-传染病学
CiteScore
3.40
自引率
4.50%
发文量
41
审稿时长
>12 weeks
期刊介绍: AIDS Reviews publishes papers reporting original scientific, clinical, epidemiologic and social research which contribute to the overall knowledge of the field of the acquired immunodeficiency syndrome and human retrovirology. Currently, the Journal publishes review articles (usually by invitation, but spontaneous submitted articles will also be considered). Manuscripts submitted to AIDS Reviews will be accepted on the understanding that the authors have not submitted the paper to another journal or published the material elsewhere.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信